Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Regen Biopharma Inc (ID)
RGBP
Healthcare
Biotechnology
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from...
autologous stromal vascular fraction from adipose tissue; dCellVax, an autologous dendritic cell treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax, which is treated with siRNA to inhibit NR2F6, with the cells re-infused into the patient; DiffronC, which uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuraCAR, comprising CAR-T cells treated with an shRNA targeting the gene NR2F6. Regen BioPharma was incorporated in 2012 and is based in La Mesa, California.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (OTCID:RGBP)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(18)
•••
AveragePenny
X
Post by
AveragePenny
on Sep 16, 2025 8:28am
Regen BioPharma Prepares Response For FDA Regarding...
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) today announced the Company is in the process of addressing comments received by the U.S
...more
(9)
•••
averagepennies
X
Post by
averagepennies
on Dec 05, 2023 11:27am
Regen BioPharma, Inc. to Present at the Emerging Growth Conf
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. SAN DIEGO,
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Dec 05, 2023 9:01am
New Press Release - Regen BioPharma, Inc. to Present at the Emerging Growth Conference on December 7, 2023
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.SAN DIEGO, Calif. , Dec. 5, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a...
read article.
(9)
•••
averagepennies
X
Post by
averagepennies
on Nov 16, 2023 10:21am
Regen BioPharma, Inc. Selects Contract Research Organization
SAN DIEGO, Nov. 16, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) The Company has announced that after interviewing several candidates it has selected
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 16, 2023 9:02am
New Press Release - Regen BioPharma, Inc. Selects Contract Research Organization to Assist in DuraCAR Experiments
SAN DIEGO, Nov. 16, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) The Company has announced that after interviewing several candidates it has selected a Contract Research Organization (CRO) to perform the next set of experiments to elucidate the effectiveness of...
read article.
(9)
•••
averagepennies
X
Post by
averagepennies
on Nov 14, 2023 10:16am
Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Pro
SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of its DuraCAR CAR T-cell therapeutic (https://www
...more
(2)
•••
Tdogzz18
X
Post by
Tdogzz18
on Nov 14, 2023 9:58am
Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Pro
SAN DIEGO, Nov. 14, 2023 SAN DIEGO, Nov. 14, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of its DuraCAR CAR T-cell
...more
(16)
•••
stockpickmover1
X
Post by
stockpickmover1
on Nov 14, 2023 9:04am
Emerging Growth Conference Regen BioPharma Inc. $RGBP
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 30, 2023 9:30am
New Press Release - Regen BioPharma, Inc. to Discuss Confirmation Study Results on Its DuraCar Program at the Emerging Growth Conference on November 1, 2023
Regen BioPharma, Inc. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference.SAN DIEGO, Calif., Oct. 30, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP), a...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 25, 2023 9:30am
New Press Release - Regen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program
Autoimmunity to be TargetedSAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc-...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 18, 2023 8:02am
New Press Release - Regen BioPharma, Inc. Expects Second Phase of Confirmatory Study Shortly
SAN DIEGO, Oct. 18, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP) is currently developing a genetic approach to regulating NR2F6 levels in human T cells. The Company has recently received unexpected and potentially extremely useful data from one of its contract...
read article.
(2)
•••
Tdogzz18
X
Post by
Tdogzz18
on Oct 12, 2023 10:59am
Global CAR T-cell Therapy Market Projected to Reach $83 Bill
Regen BioPharma, Inc. Receives First Phase of Confirmatory Study - Regen BioPharma, Inc. (OTCPK:RGBP) has previously discussed initiation of a series of experiments to validate its
...more
(12)
•••
homeyg
X
Comment by
homeyg
on Oct 11, 2023 11:53am
RE:Regen BioPharma, Inc. Receives First Phase ...
Big things coming The company has now received the first set of confirmatory data which demonstrates that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and
...more
(11)
•••
Stockhunter101
X
Post by
Stockhunter101
on Oct 10, 2023 10:21am
@RegenBioPharm $RGBP Receives First Phase Confirmatory Study
Regen BioPharma has successfully created T cells expressing chimeric antigen receptor (CAR) construct and siRNA for NR2F6, with high siRNA expression. Further studies will determine NR2F6
...more
(2)
•••
Tdogzz18
X
Post by
Tdogzz18
on Oct 10, 2023 8:34am
Regen BioPharma, Inc. Receives First Phase ...
Regen BioPharma, Inc. Receives First Phase of Confirmatory Study CAR-T Cells Created SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP
...more
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Podcasts